Oncotarget

Research Papers:

Src and STAT3 inhibitors synergize to promote tumor inhibition in renal cell carcinoma

Hui-Wen Lue _, Brook Cole, Soumya A. M. Rao, Jennifer Podalak, Ahna Van Gaest, Carly King, Christopher A. Eide, Beth Wilmot, Changhui Xue, Paul T. Spellman, Laura M. Heiser, Jeffrey W. Tyner and George V. Thomas

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2015; 6:44675-44687. https://doi.org/10.18632/oncotarget.5971

Metrics: PDF 1110 views  |   HTML 1400 views  |   ?  


Abstract

Hui-Wen Lue1,*, Brook Cole1,*, Soumya A. M. Rao1, Jennifer Podolak1, Ahna Van Gaest1, Carly King2, Christopher A. Eide3,4, Beth Wilmot5, Changhui Xue1, Paul T. Spellman6, Laura M. Heiser2, Jeffrey W. Tyner3,7, George V. Thomas1,8

1OHSU Knight Cancer Institute, Oregon Health and Science University, Portland, OR 97239, USA

2Biomedical Engineering, Oregon Health and Science University, Portland, OR 97239, USA

3Hematology and Oncology, Oregon Health and Science University, Portland, OR 97239, USA

4Howard Hughes Medical Institute, Oregon Health and Science University, Portland, OR 97239, USA

5Oregon Clinical and Translational Research Institute, Oregon Health and Science University, Portland, OR 97239, USA

6Molecular and Medical Genetics, Oregon Health and Science University, Portland, OR 97239, USA

7Cell, Developmental and Cancer Biology, Oregon Health and Science University, Portland, OR 97239, USA

8Pathology and Laboratory Medicine, Oregon Health and Science University, Portland, OR 97239, USA

*These authors have contributed equally to this work

Correspondence to:

George V. Thomas, e-mail: thomasge@ohsu.edu

Keywords: cancer, kinase inhibitors, kidney, Src, STAT3

Received: June 22, 2015     Accepted: October 04, 2015     Published: November 26, 2015

ABSTRACT

The intracytoplasmic tyrosine kinase Src serves both as a conduit and a regulator for multiple processes required for the proliferation and survival cancer cells. In some cancers, Src engages with receptor tyrosine kinases to mediate downstream signaling and in other cancers, it regulates gene expression. Src therefore represents a viable oncologic target. However, clinical responses to Src inhibitors, such as dasatinib have been disappointing to date. We identified Stat3 signaling as a potential bypass mechanism that enables renal cell carcinoma (RCC) cells to escape dasatinib treatment. Combined Src-Stat3 inhibition using dasatinib and CYT387 (a JAK/STAT inhibitor) synergistically reduced cell proliferation and increased apoptosis in RCC cells. Moreover, dasatinib and CYT387 combine to suppress YAP1, a transcriptional co-activator that promotes cell proliferation, survival and organ size. Importantly, this combination was well tolerated, and caused marked tumor inhibition in RCC xenografts. These results suggest that combination therapy with inhibitors of Stat3 signaling may be a useful therapeutic approach to increase the efficacy of Src inhibitors.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 5971